Globus Medical (GMED) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Globus Medical

NYSE•Healthcare•Medical Devices

$75.77+1.58(0.02%)After hours

Market Cap

$10.02B

P/E

18.7x

P/S

3.2x

P/B

2.1x

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

How this company scores

ExcellentMetricSide Score: 88/100

Strongest: Growth (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability23/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsRising earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.7x5y range 17.9x – 231.3x

Currently below its 20-quarter median.

P/S · 3.2x5y range 2.7x – 7.4x

Currently below its 20-quarter median.

P/B · 2.1x5y range 1.7x – 4.1x

Price & Volume

Market Cap $10.02B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $3.14B
Q. Revenue: $789.61M
TTM EBITDA: $919.01M
TTM Op. Income: $639.52M
Q. Op. Income: $182.43M
TTM Net Income: $535.43M
Q. Net Income: $151.57M
EPS: $1.12
Shares Out.: $135.05M

$3.14B in TTM revenue grew 19.7% YoY, reaching $789.61M last quarter. TTM EBITDA of $919.01M and TTM operating income of $639.52M show growth is flowing through to the bottom line. TTM net income of $535.43M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 69.4%
EBITDA Margin: 31.9%
Op. Margin: 23.1%
Net Margin: 19.2%

Op. margin of 23.1% is up 12.9% YoY — cost efficiency is improving. Net margin at 19.2% and gross margin of 69.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 126% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 18.7x
P/S Ratio: 3.2x
P/B Ratio: 2.1x

At 18.7x P/E, the stock trades within typical market levels. P/S of 3.2x and P/B of 2.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $5.49B
Cash: $507.75M
Long-Term Debt: N/A
Book Value: $4.77B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $209.74M
TTM Free Cash Flow: $755.59M
FCF Margin: 24.0%
FCF / Net Income: 1.4

TTM FCF of $755.59M on $209.74M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.